Cargando…
Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416363/ https://www.ncbi.nlm.nih.gov/pubmed/37563548 http://dx.doi.org/10.1186/s12885-023-11270-x |
| _version_ | 1785087755817058304 |
|---|---|
| author | Bozorgmehr, Farastuk Chung, Inn Christopoulos, Petros Krisam, Johannes Schneider, Marc A. Brückner, Lena Mueller, Daniel Wilhelm Thomas, Michael Rieken, Stefan |
| author_facet | Bozorgmehr, Farastuk Chung, Inn Christopoulos, Petros Krisam, Johannes Schneider, Marc A. Brückner, Lena Mueller, Daniel Wilhelm Thomas, Michael Rieken, Stefan |
| author_sort | Bozorgmehr, Farastuk |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10416363 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104163632023-08-12 Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial Bozorgmehr, Farastuk Chung, Inn Christopoulos, Petros Krisam, Johannes Schneider, Marc A. Brückner, Lena Mueller, Daniel Wilhelm Thomas, Michael Rieken, Stefan BMC Cancer Correction BioMed Central 2023-08-10 /pmc/articles/PMC10416363/ /pubmed/37563548 http://dx.doi.org/10.1186/s12885-023-11270-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Bozorgmehr, Farastuk Chung, Inn Christopoulos, Petros Krisam, Johannes Schneider, Marc A. Brückner, Lena Mueller, Daniel Wilhelm Thomas, Michael Rieken, Stefan Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial |
| title | Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial |
| title_full | Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial |
| title_fullStr | Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial |
| title_full_unstemmed | Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial |
| title_short | Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial |
| title_sort | correction: thoracic radiotherapy plus durvalumab in elderly and/or frail nsclc stage iii patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the trade-hypo trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416363/ https://www.ncbi.nlm.nih.gov/pubmed/37563548 http://dx.doi.org/10.1186/s12885-023-11270-x |
| work_keys_str_mv | AT bozorgmehrfarastuk correctionthoracicradiotherapyplusdurvalumabinelderlyandorfrailnsclcstageiiipatientsunfitforchemotherapyemployingoptimizedhypofractionatedradiotherapytofosterdurvalumabefficacystudyprotocolofthetradehypotrial AT chunginn correctionthoracicradiotherapyplusdurvalumabinelderlyandorfrailnsclcstageiiipatientsunfitforchemotherapyemployingoptimizedhypofractionatedradiotherapytofosterdurvalumabefficacystudyprotocolofthetradehypotrial AT christopoulospetros correctionthoracicradiotherapyplusdurvalumabinelderlyandorfrailnsclcstageiiipatientsunfitforchemotherapyemployingoptimizedhypofractionatedradiotherapytofosterdurvalumabefficacystudyprotocolofthetradehypotrial AT krisamjohannes correctionthoracicradiotherapyplusdurvalumabinelderlyandorfrailnsclcstageiiipatientsunfitforchemotherapyemployingoptimizedhypofractionatedradiotherapytofosterdurvalumabefficacystudyprotocolofthetradehypotrial AT schneidermarca correctionthoracicradiotherapyplusdurvalumabinelderlyandorfrailnsclcstageiiipatientsunfitforchemotherapyemployingoptimizedhypofractionatedradiotherapytofosterdurvalumabefficacystudyprotocolofthetradehypotrial AT brucknerlena correctionthoracicradiotherapyplusdurvalumabinelderlyandorfrailnsclcstageiiipatientsunfitforchemotherapyemployingoptimizedhypofractionatedradiotherapytofosterdurvalumabefficacystudyprotocolofthetradehypotrial AT muellerdanielwilhelm correctionthoracicradiotherapyplusdurvalumabinelderlyandorfrailnsclcstageiiipatientsunfitforchemotherapyemployingoptimizedhypofractionatedradiotherapytofosterdurvalumabefficacystudyprotocolofthetradehypotrial AT thomasmichael correctionthoracicradiotherapyplusdurvalumabinelderlyandorfrailnsclcstageiiipatientsunfitforchemotherapyemployingoptimizedhypofractionatedradiotherapytofosterdurvalumabefficacystudyprotocolofthetradehypotrial AT riekenstefan correctionthoracicradiotherapyplusdurvalumabinelderlyandorfrailnsclcstageiiipatientsunfitforchemotherapyemployingoptimizedhypofractionatedradiotherapytofosterdurvalumabefficacystudyprotocolofthetradehypotrial |